View Exam | PowerPak

1. Which of the following is NOT a scenario where the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes recommend consideration of a GLP-1 RA for use in patients with type 2 diabetes?

A. When there is a compelling need to minimize weight gain or promote weight loss. B. When there is a compelling need to minimize hypoglycemia. C. When there is a compelling need to decrease cardiovascular risk in patients with established ASCVD. D. When drug cost is a major consideration. E. Unsure

2. Which injectable GLP-1 RA is given the highest recommendation within the 2020 ADA Standards of Medical Care in Diabetes for weight loss based on weight reductions observed in clinical trials?

A. Dulaglutide B. Semaglutide C. Liraglutide D. Lixisenatide E. Unsure

3. The 2020 ADA Standards of Medical Care in Diabetes recommend which of the following be considered as the first injectable agent in most patients to meet individualized A1C goals?

A. Basal insulin B. Rapid-acting insulin C. Injectable GLP-1 RA D. Premix insulin product E. Unsure

4. Which GLP-1 RA demonstrated superiority for MACE and significantly decreased the risk of cardiovascular death in its large cardiovascular outcome trial (CVOT) and as a result carries an FDA indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease?

A. Exenatide XR B. Liraglutide C. Semaglutide D. Dulaglutide E. Unsure

5. Which of the following is TRUE regarding the recommended administration instructions for oral semaglutide?

A. It can be taken orally any time of day without regard to meals B. It should be taken with at least 4 ounces of fluid C. It can be crushed and mixed with applesauce for patients with swallowing difficulties D. It should be taken at least 30 minutes before the first food, beverage or other oral medication of the day E. Unsure

Evaluation Questions

6. How often do you incorporate the following into your clinical practice: Review current and emerging treatment options using the American Diabetes Association Decision Cycle for patient-centered management for patients with T2DM

A. Always B. Most of the Time C. Sometimes D. Never

7. Develop treatment plans with GLP-1 RA based on patient individual risk for ASCVD, CKD or HF and independent of A1C

A. Always B. Most of the Time C. Sometimes D. Never

8. Educate patients about therapy options with pharmacologic and nonpharmacologic strategies to aid in patient-centered decision-making treatments

A. Always B. Most of the Time C. Sometimes D. Never

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is NOT a scenario where the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes recommend consideration of a GLP-1 RA for use in patients with type 2 diabetes?

2. Which injectable GLP-1 RA is given the highest recommendation within the 2020 ADA Standards of Medical Care in Diabetes for weight loss based on weight reductions observed in clinical trials?

3. The 2020 ADA Standards of Medical Care in Diabetes recommend which of the following be considered as the first injectable agent in most patients to meet individualized A1C goals?

5. Which of the following is TRUE regarding the recommended administration instructions for oral semaglutide?

Evaluation Questions

6. How often do you incorporate the following into your clinical practice: Review current and emerging treatment options using the American Diabetes Association Decision Cycle for patient-centered management for patients with T2DM

7. Develop treatment plans with GLP-1 RA based on patient individual risk for ASCVD, CKD or HF and independent of A1C

8. Educate patients about therapy options with pharmacologic and nonpharmacologic strategies to aid in patient-centered decision-making treatments

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is NOT a scenario where the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes recommend consideration of a GLP-1 RA for use in patients with type 2 diabetes?

2. Which injectable GLP-1 RA is given the highest recommendation within the 2020 ADA Standards of Medical Care in Diabetes for weight loss based on weight reductions observed in clinical trials?

3. The 2020 ADA Standards of Medical Care in Diabetes recommend which of the following be considered as the first injectable agent in most patients to meet individualized A1C goals?

5. Which of the following is TRUE regarding the recommended administration instructions for oral semaglutide?

Evaluation Questions

6. How often do you incorporate the following into your clinical practice: Review current and emerging treatment options using the American Diabetes Association Decision Cycle for patient-centered management for patients with T2DM

7. Develop treatment plans with GLP-1 RA based on patient individual risk for ASCVD, CKD or HF and independent of A1C

8. Educate patients about therapy options with pharmacologic and nonpharmacologic strategies to aid in patient-centered decision-making treatments

« Return to Activity

Customers who Purchased
this Activity also Purchased